Vas Narasimhan, CEO of Novartis, comments on the progress of the firm’s Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
Novartis CEO says FDA’s extended approval of breast cancer drug is a ‘landmark’ for the firm
- Update Date：
- Post Date：
- Tags
